TGFβ-imprinted universal donor NK cell infusion
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TGFβ-imprinted universal donor NK cell infusion, covering 2026-01-28 to 2026-01-28. Get the full timeline:
Most recent: Clinical Trial Update: A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue [Phase 1, Phase 2]